Singleron Biotechnologies

Singleron Biotechnologies, a Yale spinout, is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques to diagnosis, health management and drug development.

Singleron aims to develop breakthrough single cell analysis solutions that can be used in clinics, drug discovery, and health management.

Singleron was founded in 2018 by Nan Fangm and Rong Fan. The company is headquartereed in Nanjing, Jiangsu, China.

 

Singleron has quickly developed key proprietary technologies and methods on microfluidic system design, tissue storage and processing, single cell barcoding and amplification, data analysis algorithms and data mining, and applied for over ten patents and software copyrights.

 

Singleron has launched its GEXSCOPE single cell RNAseq Library Prep kit, a kit enabling highly parallel single cell separation and RNA sequencing library preparation with a portable microfluidics chip and all necessary reagents, early 2020.

 

Singleron Singleron has launched its GEXSCOPE single cell RNAseq Library Prep kit, a kit enabling highly parallel single cell separation and RNA sequencing library preparation with a portable microfluidics chip and all necessary reagents, early.

 

Singleron is backed by Tencent, Sherpa Healthcare Partners, Lilly Asia Ventures, ARCH Venture Partners, China Growth Capital and others. The company raised another $30M in Series A2 round on Dec 24, 2020. This brings Singleron's total funding to $74.6M to date.

 

 

  • Year founded: 2018
  • Funding Info: $74.6M over 4 Rounds (Latest Funding Type: Series A2)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Nanjing
  • State: Jiangsu
  • Country: China
Related businesses